Concepedia

Emiko L. Kreklau

EL

13

Publications

1.2K

Citations

13

H-Index

1999

Active since

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Eli Lilly (United Kingdom)

Eli Lilly (Spain)

Eli Lilly (United States)

Indiana University School of Medicine

Emiko L. Kreklau is an author at Indiana University – Purdue University Indianapolis specializing in tumor biology, medicine, and cancer research.

Top concepts

Publications per year

1999–2019

13

Publications

13

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 555 citations · Full text

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Tinggui Yin, Marı́a José Lallena, Emiko L. Kreklau et al. · Molecular Cancer Therapeutics · 2014 · 101 citations · Full text

, , +14

A novel fluorometric oligonucleotide assay to measure O 6-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase

Emiko L. Kreklau · Nucleic Acids Research · 2001 · 96 citations · Full text

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma

S. Ma, Suzanne Egyházi, Takayuki Ueno et al. · British Journal of Cancer · 2003 · 71 citations · Full text

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Liandong Ma, Joshua R. Clayton, Richard A. Walgren et al. · Blood Cancer Journal · 2013 · 64 citations · Full text

Rows per page

1–5 of 13